Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/37228| Title: | DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. | Authors: | Low M.S.Y.;Kalff A.;Bergin K.;Coutsouvelis J.;Spencer A.;Yuen H.L.A. ;Fedele P. ;Walker P.;Grigoriadis G. | Institution: | (Yuen, Kalff, Walker, Bergin, Grigoriadis, Spencer) Department of Clinical Haematology, Alfred Health, Melbourne, Australia (Yuen, Low, Fedele, Grigoriadis) Monash Haematology, Monash Health, Melbourne, Australia (Low, Grigoriadis) Hudson Institute of Medical Research and Southern Clinical School, Monash University, Clayton, Australia (Fedele) Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia (Coutsouvelis) Centre for Medicine Use and Safety, Monash University, Clayton, Australia (Coutsouvelis) Pharmacy Department, Alfred Health, Melbourne, Australia (Spencer) Australian Centre for Blood Diseases, Monash University, Melbourne, Australia | Issue Date: | 3-Jan-2019 | Copyright year: | 2018 | Publisher: | Taylor and Francis Ltd | Place of publication: | United Kingdom | Publication information: | Leukemia and Lymphoma. 59 (12) (pp 2842-2846), 2018. Date of Publication: 02 Dec 2018. | Journal: | Leukemia and Lymphoma | Abstract: | There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1-11). The mean number of cycles of DCEP was two (range, 1-4). Overall response rate (ORR) was 55% whilst 19% achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32.8 vs. 10.7 months, p=.0004). Significant treatment-related mortality (TRM) was observed (9.7%), mostly attributable to grade 3-4 neutropenia and febrile neutropenia. Mandatory use of G-CSF is, therefore, warranted to prevent septic complications. In heavily pretreated RRMM, DCEP is an effective bridge to definitive therapy but in the absence of the latter, its value is questionable.Copyright © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/10428194.2018.1454595 | PubMed URL: | 29616871 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29616871] | ISSN: | 1042-8194 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/37228 | Type: | Article | Subjects: | neutropenia/si [Side Effect] priority journal retrospective study sepsis/si [Side Effect] thrombocytopenia/si [Side Effect] thrombosis/si [Side Effect] treatment response unspecified side effect/si [Side Effect] bortezomib/cb [Drug Combination] bortezomib/dt [Drug Therapy] *cisplatin/ae [Adverse Drug Reaction] *cisplatin/cb [Drug Combination] *cisplatin/dt [Drug Therapy] *cisplatin/iv [Intravenous Drug Administration] *cyclophosphamide/ae [Adverse Drug Reaction] *cyclophosphamide/cb [Drug Combination] *cyclophosphamide/dt [Drug Therapy] *cyclophosphamide/iv [Intravenous Drug Administration] *dexamethasone/ae [Adverse Drug Reaction] *dexamethasone/cb [Drug Combination] *dexamethasone/dt [Drug Therapy] *dexamethasone/po [Oral Drug Administration] *etoposide/ae [Adverse Drug Reaction] *etoposide/cb [Drug Combination] *etoposide/dt [Drug Therapy] *etoposide/iv [Intravenous Drug Administration] granulocyte colony stimulating factor/dt [Drug Therapy] lenalidomide/cb [Drug Combination] lenalidomide/dt [Drug Therapy] thalidomide/cb [Drug Combination] thalidomide/dt [Drug Therapy] tumor lysis syndrome/si [Side Effect] adult *advanced cancer/dt [Drug Therapy] *advanced cancer/th [Therapy] aged anemia/si [Side Effect] article autologous stem cell transplantation *cancer combination chemotherapy febrile neutropenia/dt [Drug Therapy] febrile neutropenia/pc [Prevention] febrile neutropenia/si [Side Effect] female heart disease/si [Side Effect] herpes zoster/si [Side Effect] human major clinical study male multiple cycle treatment *multiple myeloma/dt [Drug Therapy] *multiple myeloma/th [Therapy] mycosis/si [Side Effect] mycosis / side effect neutropenia / side effect priority journal retrospective study sepsis / side effect thrombocytopenia / side effect thrombosis / side effect treatment response tumor lysis syndrome / side effect unspecified side effect / side effect autologous stem cell transplantation Article anemia / side effect *cancer combination chemotherapy *advanced cancer / *drug therapy / *therapy adult aged febrile neutropenia / drug therapy / prevention / side effect female heart disease / side effect herpes zoster / side effect human major clinical study male multiple cycle treatment *multiple myeloma / *drug therapy / *therapy |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.